0 271

Cited 0 times in

Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study

Authors
 Hyung-Don Kim  ;  Jong Seok Lee  ;  Young Soo Park  ;  Jeong Hwan Yook  ;  Sung Hoon Noh  ;  Young-Kyu Park  ;  Young-Woo Kim  ;  Sang Cheul Oh  ;  Jong Gwang Kim  ;  Min-Hee Ryu  ;  Jae-Ho Cheong  ;  HyunKi Kim  ;  Joon Seok Lim  ;  Jae-Hyuk Lee  ;  Suk Hee Heo  ;  Jin Young Kim  ;  Mi Hwa Heo  ;  Young Iee Park  ;  In-Ho Kim  ;  Yoon-Koo Kang 
Citation
 GASTRIC CANCER, Vol.25(6) : 1039-1049, 2022-11 
Journal Title
GASTRIC CANCER
ISSN
 1436-3291 
Issue Date
2022-11
MeSH
Antineoplastic Combined Chemotherapy Protocols / therapeutic use ; Humans ; Middle Aged ; Neoadjuvant Therapy* ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Stomach Neoplasms* / drug therapy ; Stomach Neoplasms* / surgery ; Survival Rate
Keywords
Clinical stage ; Gastric cancer ; Neoadjuvant chemotherapy ; Post-neoadjuvant chemotherapy pathological stage
Abstract
Background: In this post hoc analysis of the PRODIGY study, we aimed to investigate factors associated with survival outcomes and provide evidence for designing optimal perioperative treatment strategies for gastric cancer patients receiving neoadjuvant chemotherapy.

Patients and methods: A total of 212 patients in the neoadjuvant chemotherapy group of the PRODIGY study were included as the study population. The prognostic impact of clinicopathologic factors, including the initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage), was analyzed.

Results: The median age was 58 years. The majority of patients (77.4%) had cStage III disease, and about 10% and 25% had ypStage 0 and I disease, respectively. According to the initial cStage, progression-free survival (PFS) and overall survival (OS) were significantly different (P < 0.01). PFS and OS were also different according to the ypStage (P < 0.01). In multivariate analyses, cStage IIIC disease (vs. cStage II) and ypStage II and III disease (vs. ypStage 0/I) were independent factors for poor survival outcomes. Based on the patterns of PFS and OS according to both cStage and ypStage, three patient groups were defined. These groups showed distinct PFS and OS (P < 0.01) with 5-year PFS rates of 95.7%, 77.9%, and 31.3% and 5-year OS rates of 95.7%, 82.4%, and 42.5%, respectively.

Conclusions: Both initial cStage and ypStage were independent factors for survival outcomes of gastric cancer patients treated with neoadjuvant chemotherapy. Efforts should be made to develop optimal peri-operative treatment strategies for patients at different risks according to cStage and ypStage.
Full Text
https://link.springer.com/article/10.1007/s10120-022-01325-6
DOI
10.1007/s10120-022-01325-6
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyunki(김현기) ORCID logo https://orcid.org/0000-0003-2292-5584
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Lim, Joon Seok(임준석) ORCID logo https://orcid.org/0000-0002-0334-5042
Cheong, Jae Ho(정재호) ORCID logo https://orcid.org/0000-0002-1703-1781
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/194435
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links